NCT06846268View on ClinicalTrials.gov

Neoadjuvant ADG126 and Pembrolizumab in Locally Advanced Colorectal Cancer

PHASE2RecruitingINTERVENTIONAL
Enrollment

20

Participants

Timeline

Start Date

April 14, 2025

Primary Completion Date

December 31, 2027

Study Completion Date

December 31, 2027

Conditions
Locally Advanced Colorectal Cancer
Interventions
DRUG

ADG126

Administered via intravenous infusion on Day 1 only (Q6W) or Day 1 and Day 22 (Q3W).

DRUG

Pembrolizumab

Administered via intravenous infusion on Day 1 and Day 22.

Trial Locations (1)

119074

RECRUITING

National University Hospital, Singapore

Sponsors

Collaborators (1)

Adagene Inc
All Listed Sponsors
collaborator

Adagene Inc

INDUSTRY

lead

National University Hospital, Singapore

OTHER

NCT06846268 - Neoadjuvant ADG126 and Pembrolizumab in Locally Advanced Colorectal Cancer | Biotech Hunter | Biotech Hunter